Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

852 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
Gitt AK, Drexel H, Feely J, Ferrières J, Gonzalez-Juanatey JR, Thomsen KK, Leiter LA, Lundman P, da Silva PM, Pedersen T, Wood D, Jünger C, Dellea PS, Sazonov V, Chazelle F, Kastelein JJ; DYSIS Investigators. Gitt AK, et al. Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10. Eur J Prev Cardiol. 2012. PMID: 21450578
Cardiac rehabilitation of elderly patients in eight rehabilitation units in western Europe: Outcome data from the EU-CaRE multi-centre observational study.
Prescott E, Eser P, Mikkelsen N, Holdgaard A, Marcin T, Wilhelm M, Gil CP, González-Juanatey JR, Moatemri F, Iliou MC, Schneider S, Schromm E, Zeymer U, Meindersma EP, Crocamo A, Ardissino D, Kolkman EK, Prins LF, van der Velde AE, Van't Hof AW, de Kluiver EP. Prescott E, et al. Eur J Prev Cardiol. 2020 Nov;27(16):1716-1729. doi: 10.1177/2047487320903869. Epub 2020 Feb 26. Eur J Prev Cardiol. 2020. PMID: 32102550
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Cardiac rehabilitation in the elderly patient in eight rehabilitation units in Western Europe: Baseline data from the EU-CaRE multicentre observational study.
Prescott E, Mikkelsen N, Holdgaard A, Eser P, Marcin T, Wilhelm M, Gil CP, González-Juanatey JR, Moatemri F, Iliou MC, Schneider S, Schromm E, Zeymer U, Meindersma EP, Ardissino D, Kolkman EK, Prins LF, van der Velde AE, Van 't Hof AW, de Kluiver EP. Prescott E, et al. Eur J Prev Cardiol. 2019 Jul;26(10):1052-1063. doi: 10.1177/2047487319839819. Epub 2019 Mar 29. Eur J Prev Cardiol. 2019. PMID: 30924688
A EUropean study on effectiveness and sustainability of current Cardiac Rehabilitation programmes in the Elderly: Design of the EU-CaRE randomised controlled trial.
Prescott E, Meindersma EP, van der Velde AE, Gonzalez-Juanatey JR, Iliou MC, Ardissino D, Zoccai GB, Zeymer U, Prins LF, Van't Hof AW, Wilhelm M, de Kluiver EP. Prescott E, et al. Eur J Prev Cardiol. 2016 Oct;23(2 suppl):27-40. doi: 10.1177/2047487316670063. Eur J Prev Cardiol. 2016. PMID: 27892423 Clinical Trial.
Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry.
Caro-Codón J, López-Fernández T, Álvarez-Ortega C, Zamora Auñón P, Rodríguez IR, Gómez Prieto P, Buño Soto A, Canales Albendea M, Albaladejo A, Mediavilla G, Feliu Batlle J, Rodríguez Fraga O, Martínez Monzonis A, González-Costello J, Serrano Antolín JM, Cadenas Chamorro R, González-Juanatey JR, López-Sendón J; CARDIOTOX registry investigators. Caro-Codón J, et al. Eur J Prev Cardiol. 2022 May 6;29(6):859-868. doi: 10.1093/eurjpc/zwaa034. Eur J Prev Cardiol. 2022. PMID: 33624069
Offering, participation and adherence to cardiac rehabilitation programmes in the elderly: a European comparison based on the EU-CaRE multicentre observational study.
González-Salvado V, Peña-Gil C, Lado-Baleato Ó, Cadarso-Suárez C, Prada-Ramallal G, Prescott E, Wilhelm M, Eser P, Iliou MC, Zeymer U, Ardissino D, Bruins W, van der Velde AE, Van't Hof AWJ, de Kluiver EP, Kolkman EK, Prins L, González Juanatey JR. González-Salvado V, et al. Eur J Prev Cardiol. 2021 May 14;28(5):558-568. doi: 10.1093/eurjpc/zwaa104. Eur J Prev Cardiol. 2021. PMID: 33558875
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
852 results